|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2001-2-7
|
|
pubmed:abstractText |
Administration of flumazenil, a benzodiazepine (BZD) antagonist, has therapeutic efficacy against some anxiogenic effects of ethanol withdrawal. This observation has led to the suggestion that anxiety associated with ethanol withdrawal is related to release in brain of an endogenous BZD inverse agonist.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0033-3158
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
152
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
208-15
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11057525-Animals,
pubmed-meshheading:11057525-Carbolines,
pubmed-meshheading:11057525-Ethanol,
pubmed-meshheading:11057525-Flumazenil,
pubmed-meshheading:11057525-Male,
pubmed-meshheading:11057525-Proto-Oncogene Proteins c-fos,
pubmed-meshheading:11057525-Rats,
pubmed-meshheading:11057525-Rats, Sprague-Dawley,
pubmed-meshheading:11057525-Receptors, GABA-A,
pubmed-meshheading:11057525-Substance Withdrawal Syndrome,
pubmed-meshheading:11057525-Vocalization, Animal
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Enhanced ultrasonic vocalization and Fos protein expression following ethanol withdrawal: effects of flumazenil.
|
|
pubmed:affiliation |
Skipper Bowles Center for Alcohol Studies, Department of Psychiatry and UNC Neuroscience Center, UNC School of Medicine, Chapel Hill, NC 27599, USA. sheryl.moy@css.unc.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
